DNLI · Denali Therapeutics Inc.
$24.67
+0.10 (+0.39%)
At close · Aug 27
Market Cap
$3.95B
Shares
159.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.57
Open$24.75
Day$24.33–24.89
52W close$12.75–27.21
Avg vol 30d1.3M
Short int18.0M · 11.2% float · 12.4d
Short vol71%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Dec 23, 2026
Est · unconfirmed
· in 17 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
+0%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
82%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+25%
trailing
YTD return
+49%
this year
Relative strength
+12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$71.6K over 90 days · 100% sells
Short interest
Rising
11.24% of float · ▲ +3.0% MoM · 12.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
293 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
−16%
Y/Y
Free cash flow
$-422.1M
Balance sheet
$205.3M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
AVLAYAH net product revenue
· third quarter 2026
Initiated
$10M – $12M
Prior guidance
period ended
· from the 8-K filed Feb 27, 2025
Cash operating expenses
· 2025
10% – 15%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
82%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $25 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$71.6K over 90 days · 100% sells
Short interest
Rising
11.24% of float · ▲ +3.0% MoM · 12.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
293 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $25 · 82%
Range high $27
vs 200-day avg +19%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Enrollment in the study | 40 | Phase 1/2 study | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNLI
this stock
Denali Therapeutics Inc.
|
$3.95B | +48.8% | — | — | 11.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNLI | -4.4% | +3.0% | +24.7% | +6.7% | +48.8% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -4.0% | -2.0% | +12.3% | +4.2% | +36.5% |
Key facts
CIK
1714899
CUSIP
24823R105
13F (30d)
248 filings
247 filers
Visit website
Investor relations